The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 02, 2022
Filed:
Jul. 28, 2017
Applicant:
Mayo Foundation for Medical Education and Research, Rochester, MN (US);
Inventors:
Wolfdieter Springer, Neptune Beach, FL (US);
Fabienne C. Fiesel, Neptune Beach, FL (US);
Thomas R. Caulfield, Jacksonville, FL (US);
Assignee:
Mayo Foundation for Medical Education and Research, Rochester, MN (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 213/56 (2006.01); C07D 233/64 (2006.01); C07D 235/16 (2006.01); C07D 257/04 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 409/14 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 471/10 (2006.01); C07D 487/04 (2006.01); C07D 498/04 (2006.01); C12N 9/00 (2006.01); A61P 25/00 (2006.01); A61P 25/16 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07D 401/04 (2013.01); A61P 25/00 (2018.01); A61P 25/16 (2018.01); A61P 35/00 (2018.01); C07D 213/56 (2013.01); C07D 233/64 (2013.01); C07D 235/16 (2013.01); C07D 257/04 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 409/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 498/04 (2013.01); C12N 9/93 (2013.01); C12Y 603/02019 (2013.01);
Abstract
The present disclosure relates to compounds for activating the enzymatic activity of an E3 ubiquitin ligase and methods for treating a disease or disorder in a subject with diminished E3 ubiquitin ligase enzymatic activity. In some embodiments, the present disclosure provides a compound of Formula (I) or a compound of Formula (II) or pharmaceutically acceptable salts thereof.